Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 3748

1.

Economic burden of bilateral neovascular age-related macular degeneration: multi-country observational study.

Cruess AF, Zlateva G, Xu X, Soubrane G, Pauleikhoff D, Lotery A, Mones J, Buggage R, Schaefer C, Knight T, Goss TF.

Pharmacoeconomics. 2008;26(1):57-73.

PMID:
18088159
2.

Burden of illness of bilateral neovascular age-related macular degeneration in Spain.

Ruiz-Moreno JM, Coco RM, García-Arumí J, Xu X, Zlateva G.

Curr Med Res Opin. 2008 Jul;24(7):2103-11. doi: 10.1185/03007990802214300 . Epub 2008 Jun 10.

PMID:
18547463
3.

[Humanistic burden and health resource utilization among neovascular age-related macular degeneration patients in France].

Soubrane G, Zlateva G, Xu X, Buggage R, Kosa M.

J Fr Ophtalmol. 2008 Feb;31(2):138-45. French.

4.

Evaluation of non-medical costs associated with visual impairment in four European countries: France, Italy, Germany and the UK.

Lafuma A, Brézin A, Lopatriello S, Hieke K, Hutchinson J, Mimaud V, Berdeaux G.

Pharmacoeconomics. 2006;24(2):193-205.

PMID:
16460138
5.

Association between visual acuity and medical and non-medical costs in patients with wet age-related macular degeneration in France, Germany and Italy.

Bandello F, Augustin A, Sahel JA, Benhaddi H, Negrini C, Hieke K, Berdeaux GH; MICMAC (MICro-economics of MACular degeneration) Study Group.

Drugs Aging. 2008;25(3):255-68.

PMID:
18331076
6.

Burden and health care resource utilization in neovascular age-related macular degeneration: findings of a multicountry study.

Soubrane G, Cruess A, Lotery A, Pauleikhoff D, Monès J, Xu X, Zlateva G, Buggage R, Conlon J, Goss TF.

Arch Ophthalmol. 2007 Sep;125(9):1249-54.

PMID:
17846366
7.

Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.

Coleman AL, Yu F.

Ophthalmology. 2008 Jan;115(1):18-25. Epub 2007 Jun 18.

PMID:
17572499
8.

Burden of illness of neovascular age-related macular degeneration in Canada.

Cruess A, Zlateva G, Xu X, Rochon S.

Can J Ophthalmol. 2007 Dec;42(6):836-43.

PMID:
18026200
9.

The burden of age-related macular degeneration: results of a cohort study in two French referral centres.

Bonastre J, Le Pen C, Soubrane G, Quentel G.

Pharmacoeconomics. 2003;21(3):181-90.

PMID:
12558468
10.

The economic impact of overactive bladder syndrome in six Western countries.

Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C.

BJU Int. 2009 Jan;103(2):202-9. doi: 10.1111/j.1464-410X.2008.08036.x.

11.

[Neovascular age-related macular degeneration in Germany. Encroachment on the quality of life and the financial implications].

Pauleikhoff D, Scheider A, Wiedmann P, Gelisken F, Scholl HP, Roider I, Mohr A, Zlateva G, Xu X.

Ophthalmologe. 2009 Mar;106(3):242-51. doi: 10.1007/s00347-008-1797-9. German.

PMID:
18709375
12.

The burden of age-related macular degeneration.

Schmier JK, Jones ML, Halpern MT.

Pharmacoeconomics. 2006;24(4):319-34. Review.

PMID:
16605279
13.

Cost of depression in Europe.

Sobocki P, Jönsson B, Angst J, Rehnberg C.

J Ment Health Policy Econ. 2006 Jun;9(2):87-98.

PMID:
17007486
14.

Vision-related quality of life in patients with bilateral severe age-related macular degeneration.

Cahill MT, Banks AD, Stinnett SS, Toth CA.

Ophthalmology. 2005 Jan;112(1):152-8.

PMID:
15629836
15.

Costs and quality of life of multiple sclerosis in Austria.

Kobelt G, Berg J, Lindgren P, Plesnilla C, Baumhackl U, Berger T, Kolleger H, Vass K.

Eur J Health Econ. 2006 Sep;7 Suppl 2:S14-23.

PMID:
17310339
16.

Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.

Schädlich PK, Zeidler H, Zink A, Gromnica-Ihle E, Schneider M, Straub C, Brecht JG, Huppertz E.

Pharmacoeconomics. 2005;23(4):377-93.

PMID:
15853437
17.

Relative cost of a line of vision in age-related macular degeneration.

Smiddy WE.

Ophthalmology. 2007 May;114(5):847-54. Epub 2007 Feb 16. Review.

PMID:
17306878
18.

Depression, visual acuity, comorbidity, and disability associated with age-related macular degeneration.

Brody BL, Gamst AC, Williams RA, Smith AR, Lau PW, Dolnak D, Rapaport MH, Kaplan RM, Brown SI.

Ophthalmology. 2001 Oct;108(10):1893-900; discussion 1900-1.

PMID:
11581068
19.

[Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].

Neubauer AS, Holz FG, Schrader W, Back EI, Kühn T, Hirneiss C, Kampik A.

Klin Monbl Augenheilkd. 2007 Sep;224(9):727-32. German.

PMID:
17846963
20.

Cost of illness and its predictors for Parkinson's disease in Germany.

Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, Koehne-Volland R, Rieke J, Simonow A, Brandstaedter D, Siebert U, Oertel WH, Ulm G, Dodel R.

Pharmacoeconomics. 2005;23(8):817-36.

PMID:
16097843

Supplemental Content

Support Center